健康元：健康元药业集团股份有限公司2024年第一季度报告（英文版）

StockCode:600380StockShortName:健康元 JoincarePharmaceuticalGroupIndustryCo.,Ltd. 2024FirstQuarterlyReport TheBoardofDirectorsandallDirectorsoftheCompanyherebywarrantthattherearenofalserepresentations,misleadingstatementsormaterialomissionscontainedinthisannouncementandacceptlegalresponsibilityforthetruthfulness,accuracyandcompletenessofthecontentshereof. IMPORTANTNOTICE: TheBoardofDirectors,theBoardofSupervisorsandDirectors,SupervisorsandseniormanagementoftheCompanyherebywarrantthetruthfulness,accuracyandcompletenessofthecontentsofthisquarterlyreport,andthattherearenofalserepresentations,misleadingstatementsormaterialomissionscontainedherein,andseverallyandjointlyacceptlegalresponsibility. Theperson-in-chargeoftheCompany,theperson-in-chargeofaccountingworkandtheperson-in-chargeoftheaccountingdepartment(theheadoftheaccountingdepartment)herebywarrantthetruthfulness,accuracyandcompletenessofthefinancialinformationcontainedinthisquarterlyreport. Whetherthefirstquarterlyfinancialstatementshavebeenaudited. □Yes√No I.MAJORFINANCIALDATA (I)MajorAccountingDataandFinancialIndicators Unit:YuanCurrency:RMB Item TheReportingPeriod(FromJanuarytoMarch) YoYchange(%) Revenues 4,339,814,452.16 -4.81 Netprofitattributabletoshareholdersofthelistedcompany 439,798,106.55 -4.96 Netprofitattributabletoshareholdersofthelistedcompanyafterdeductionofextraordinarygainsandlosses 427,753,549.19 -4.26 Netcashflowfromoperatingactivities 972,276,972.65 291.91 Basicearningspershare(RMB/share) 0.2357 -1.96 Dilutedearningspershare(RMB/share) 0.2355 -1.82 Weightedaveragereturnonnetassets(%) 3.15 Decreasedby0.34percentagepoints AsattheendoftheReportingPeriod Asattheendofthepreviousyear ChangeasattheendoftheReportingPeriodascomparedtotheendofthe previousyear(%) Totalassets 36,462,147,240.89 36,358,126,258.82 0.29 Owner'sequityattributabletoshareholdersofthelistedcompany 14,234,869,509.55 13,755,901,924.06 3.48 Notes:FromJanuarytoMarch2024,theCompanyChemicalpharmaceuticalsrealizedrevenuesofRMB2,141million,representingaYoYdecreaseof4.86%,amongwhich,RMB807millionwerefromgonadotropichormones,representingaYoYincreaseof39.89%;RMB589millionwerefromgastroenterologyproducts,representingaYoYdecreaseof25.68%;RMB417millionwerefromrespiratoryformulationproducts,representingaYoYdecreaseof18.17%;RMB135millionwerefrompsychiatryproducts,representingaYoYincreaseof10.11%;andRMB115millionwerefromanti-infectionproducts,representingaYoYdecreaseof42.20%.APIsandintermediatesproductsrealizedrevenuesofRMB1,399million,representingaYoYdecreaseof3.70%.TraditionalChineseMedicineproductsrealizedrevenuesofRMB406million,representingaYoYdecreaseof28.38%.DiagnosticreagentsandequipmentproductsrealizedrevenuesofRMB236millionfrom,representingaYoYincreaseof60.26%.HealthcareproductsrealizedrevenuesofRMB78million,representingaYoYincreaseof96.50%.BiologicalproductsrealizedrevenuesofRMB44million,representingaYoYdecreaseof29.86%. (II)ItemsandAmountsofExtraordinaryGainsandLosses Unit:YuanCurrency:RMB Item FortheReportingPeriod Explanation Gainsandlossesondisposalofnon-currentassets(includingthereversalofassetimpairmentprovisionsalreadyrecognized) 306,572.18 Proceedsfromdisposaloffixedassets Governmentgrantsrecognizedinprofitandlossforcurrentperiod(exceptforgovernmentgrantscloselyassociatedwithcorporatebusinesses,entitledatfixedamountorfixedlevelaccordingtothenationalpolicesandstandards) 23,948,950.14 GovernmentgrantsthroughtheprofitsandlossesforthePeriod Gainsandlossesonfairvaluechangesincurredfromfinancialassetsheldfortrading,derivativefinancialassets,financialliabilitiesheldfortradingandderivativefinancialliabilities,andinvestmentincomeondisposaloffinancialassetsheldfortrading,derivativefinancialassets,financialliabilitiesheldfortrading,derivativefinancialliabilitiesandotherdebtinvestments,exceptforeffectivehedgingactivitiesrelatedtotheordinaryoperatingbusinessoftheCompany 3,385,577.72 Gainsorlossesarisingfromchangesinfairvalueoffinancialassets/liabilitiesheldfortrading,andinvestmentgainsfromholdinganddisposaloffinancialassets/liabilitiesheldfortrading Othernon-operatingincomeandexpensesapartfromtheaboveitems -3,998,396.15 Othernon-operatingincomeandexpensesexcludingtheaboveitems Less:Effectofincometax 1,860,588.22 Effectoftheaboveitemsonincometax Effectofminorityequity(aftertax) 9,737,558.31 Theportionoftheaboveitemstowhichminorityshareholdersareentitled Total 12,044,557.36 ExplanationsforsignificantamountofextraordinarygainorlossitemsidentifiedbytheCompanybutnotlistedinthe“ExplanatoryAnnouncementNo.1forPublicCompanyInformationDisclosures–ExtraordinaryGainsorLosses”,andrecurringgainorlossitemsidentifiedbytheCompanywhicharelistedasextraordinarygainorlossitemsinthe“ExplanatoryAnnouncementNo.1forPublicCompanyInformationDisclosures–ExtraordinaryGainsorLosses”. □Applicable√N/A (III)ChangesinMajorAccountingDataandFinancialIndicatorsandReasonsThereof √Applicable□N/A Item Change(%) Explanation Netcashflowfromoperatingactivities 291.91 Mainlyduetothedecreaseinprocurementandexpens